Izalontamab brengitecan, a first-in-class bispecific antibody-drug conjugate targeting EGFR and HER3, achieved an overall response rate of 48.1% in patients with relapsed extensive-stage small cell lung cancer, according to phase Ib results published in the Journal of Clinical Oncology by Zhao et al. (2026). The data, drawn from an expansion cohort of the open-label trial NCT05194982, indicate pronounced activity in earlier treatment lines, offering a fresh investigational avenue for thoracic oncologists managing a disease where subsequent options typically yield short-lived benefits.
Clinical Trial Design and Patient Demographics in the Phase Ib Cohort
The study evaluated 52 patients with histologically or cytologically confirmed extensive-stage small cell lung cancer who experienced disease progression after prior systemic treatment, according to Zhao et al. (2026). Participants received the agent, also known as iza-bren or BL-B01D1, at a dose of 2.5 mg/kg intravenously on days 1 and 8 of a three-week cycle. The median patient age stood at 60.5 years, with men comprising 80.8% of the cohort. Nearly all participants held an Eastern Cooperative Oncology Group performance status of 1. Every patient had received prior platinum-based chemotherapy, and 84.6% had previously been treated with anti–PD-1 or anti–PD-L1 immunotherapy. Furthermore, 17 patients presented with brain metastases at screening, though active central nervous system lesions were excluded from participation.
Second-Line Treatment Efficacy and Survival Outcomes
The most compelling signal emerged among the 22 patients who received iza-bren as a second-line therapy, where the objective response rate reached 72.7%, according to Zhao et al. (2026). Within this subgroup, the disease control rate hit 90.9%, median progression-free survival extended to 6.2 months, and median overall survival reached 15.0 months. By comparison, the 30 patients who received the drug across two or more prior lines showed an objective response rate of 30.0%, a median progression-free survival of 3.0 months, and a median overall survival of 10.3 months. Across the entire cohort of 52 patients, the objective response rate was 48.1%, the disease control rate was 80.8%, median progression-free survival registered at 4.1 months, and median overall survival stood at 12.2 months.
“These results require confirmation in a randomized trial, but they position dual EGFR-HER3 targeting as a new investigational strategy in relapsed SCLC,” according to Zhao et al. (2026).
Toxicity Profile and Management of Hematologic Adverse Events
Hematologic toxicity served as the primary safety challenge during the trial, requiring careful clinical management through supportive care, treatment delays, and dose modifications, according to Zhao et al. (2026). Anemia occurred in 84.6% of patients, thrombocytopenia in 75.0%, leukopenia in 73.1%, and neutropenia in 71.2%. Non-hematologic toxicities included stomatitis in 36.5% of participants, alongside nausea, vomiting, diarrhea, electrolyte abnormalities, fatigue, and reduced appetite. Investigators noted that while manageable in a clinical trial setting, the frequency of severe hematologic events demands close evaluation as the drug moves into randomized phase III testing.
Biomarker Exploration and HER3 Expression Patterns
Exploratory biomarker analyses provided preliminary clues regarding patient selection, though tissue samples were available for only 26 patients, with 23 evaluable for response, according to Zhao et al. (2026). EGFR expression failed to distinguish responders from non-responders, showing an objective response rate of 50.0% in EGFR-positive tumors and 53.8% in EGFR-negative tumors. Conversely, HER3 expression showed a distinct pattern: patients with HER3-positive tumors achieved an objective response rate of 68.8%, compared to 14.3% among those with HER3-negative tumors. The authors emphasized that while these findings suggest HER3 abundance may align with cytotoxicity, the biomarker cohort was small and uniform tissue collection was lacking.
Next Steps in Randomized Phase III Evaluation
To establish definitive comparative evidence, a randomized phase III trial designated NCT06500026 is currently evaluating iza-bren against topotecan in previously treated small cell lung cancer, according to Zhao et al. (2026). This upcoming trial will determine if the high response rates observed in the phase Ib cohort translate into verified survival advantages. It will also expand the safety dataset and clarify whether prospective HER3 testing can reliably identify patients most likely to benefit from the bispecific antibody-drug conjugate.
Did you know?
Unlike conventional antibody-drug conjugates in small cell lung cancer that primarily target neuroendocrine markers like DLL3 and B7-H3, iza-bren pairs a bispecific immunoglobulin G1 backbone with a topoisomerase I inhibitor payload to target both EGFR and HER3 simultaneously (Zhao et al., 2026).
Frequently Asked Questions
What is izalontamab brengitecan (iza-bren)?
Iza-bren is a first-in-class bispecific antibody-drug conjugate that targets both EGFR and HER3, carrying a topoisomerase I inhibitor payload linked via a cleavable linker with a drug-to-antibody ratio of eight, according to Zhao et al. (2026).
What response rate did iza-bren show in the phase Ib trial?
According to Zhao et al. (2026), the overall objective response rate across 52 patients was 48.1%, with a notably higher response rate of 72.7% observed in patients receiving the drug in the second-line setting.
What are the primary safety concerns associated with iza-bren?
The most frequent adverse events are hematologic, including anemia at 84.6%, thrombocytopenia at 75.0%, leukopenia at 73.1%, and neutropenia at 71.2%, which investigators managed through dose modifications and supportive care (Zhao et al., 2026).
How is iza-bren being evaluated next?
An ongoing randomized phase III trial, NCT06500026, is comparing iza-bren directly against topotecan in patients with previously treated small cell lung cancer, according to Zhao et al. (2026).
Explore more clinical updates in thoracic oncology or subscribe to our newsletter for weekly updates on emerging cancer therapeutics.
Worth a look